IDEAYA Biosciences IPO

5/22/2019

IPO

$50,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $27.0 million to $32.0 million to fund the clinical development of IDE196 (our protein kinase C, or PKC, inhibitor), including potential milestone payments to Novartis, through [i] completion of enrollment and interim data of the Phase 1/2 clinical trial in multiple solid tumor indications based on a tissue-type agnostic basket trial design for patients with solid tumors that have mutations in GNAQ or GNA11, or PKC gene fusions, as well as [ii] completion of preclinical evaluation for potential therapeutic use in NSCLC for patients having tumors with resistance to an EGFR inhibitor mediated by PKC, as well as [iii] completion of preclinical evaluation, and subject to satisfactory results from such preclinical evaluation, initiation of a clinical trial evaluating IDE196 in combination with one or more additional anti-cancer agent[s] in patients with metastatic uveal melanoma; approxi

Publicly-held

Biopharmaceutical

7000 Shoreline Ct. 350
San Francisco, CA 94080
USA

IDEAYA Biosciences (Nasdaq: IDYA). At the core of a successful big biology and small molecule based drug discovery company is well understood pathobiology of the drug targets and excellent chemical matter to modulate them - one without the other ultimately equals failure.